| |
| | | PWC | | PricewaterhouseCoopers | | | Biotech reinvented. Where do you go from here? | | Pharmaceuticals and Life Sciences | | | PricewaterhouseCoopers | | 2010 | | | "(...) The biotechnology industry (Biotech) is now about 30 years old - a long enough time in which to evaluate how it?s done. Unfortunately, despite some notable successes, it hasn?t completely fulfilled its promise. The business model on which Biotech has historically relied is also breaking down, as the research base moves east and raising funds gets harder. And the
distinctions between Biotech and the pharmaceutical industry (Pharma) are disappearing, with the convergence of the two sectors. But Biotech can?t turn to Pharma for guidance because
Pharma?s business model has other flaws - as we explained in "Pharma 2020: Challenging business models?, the White Paper we published in April 2009.1 So what should Biotech do? We believe it should capitalise on the opportunities emerging in the healthcare arena - and reinvent itself by adopting a more collaborative approach. In the following pages, we?ll look at the main trends dictating the need for a new way of conducting Research and development (R&D), and two organisational concepts that would help biopharmaceutical companies become far more efficient. We?ll also touch on the implications for other parts of the value chain. (...)"
[Foresight] | | | hier klicken (PDF 497 KB) | | PricewaterhouseCoopers | |
|
| |